search
Back to results

Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients (on-line-HDF)

Primary Purpose

Cardiovascular Disease

Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
On line Hemodiafiltration
Hemodialysis
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiovascular Disease focused on measuring on line hemodiafiltration, tolerance, quality of life, cardiovascular risk, Hemodialysis patients

Eligibility Criteria

65 Years - 90 Years (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient who has signed the written consent form
  • Patient aged > 65 and < 90 years
  • With creatinine clearance < 10 mL/min
  • On dialysis for a minimum of 3 months, with 3 times a week hemodialysis sessions
  • Erythropoietin dosage needed to maintain hemoglobin at a constant level (range of hemoglobin: 9-13 g/dL without any variation of more than 2g/dL for less than 3 months)
  • Without any problem of vascular access

Exclusion Criteria:

  • Patient aged < 65 and > 90 years
  • Presence of severe malnutrition (albumin < 20 g/L)
  • Unstable clinical condition
  • Unipuncture or failed vascular access flow
  • Known problems of coagulation

Sites / Locations

  • Centre Hospitalier Universitaire

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Other

Arm Label

On line Hemodiafiltration

hemodialysis

Arm Description

Hemodialysis patients treated with on line hemodiafiltration technic

Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers

Outcomes

Primary Outcome Measures

tolerance of "on line" HDF treatment versus conventional high flux hemodialysis in term of adverse events occuring during dialysis sessions

Secondary Outcome Measures

Quality of life evaluated with the KDQOL questionnaire
Incidence of cardiovascular events
Influence of the technic on mineral metabolism disturbances
measure of mineral metabolism parameters (Ca, PO4, PTH)
All cause and cardiovascular mortality
Influence of the technic on inflammatory parameters
measure of pro-inflammatory cytokines and acute phase reactant proteins
Influence of the technic on microbiological safety
measure of microbiological purity of dialysate
Influence of the technic on oxidative stress parameters
measure of oxidative stress markers (AOPP, AGE) and antioxidant systems (vitamin E)

Full Information

First Posted
January 14, 2008
Last Updated
December 5, 2014
Sponsor
University Hospital, Montpellier
Collaborators
Ministry of Health, France
search

1. Study Identification

Unique Protocol Identification Number
NCT01327391
Brief Title
Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients
Acronym
on-line-HDF
Official Title
Tolerance of "on Line" Hemodiafiltration and Impact on Morbidity and Cardiovascular Risk Factors in Chronic Renal Failure Patients
Study Type
Interventional

2. Study Status

Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
May 2005 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
Collaborators
Ministry of Health, France

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to appreciate the tolerance of "on line" hemodiafiltration and its impact on morbidity and cardiovascular risk factors in chronic renal failure patient.
Detailed Description
The aim of this study is to appreciate the tolerance of "on line" HDF treatment versus conventional high flux hemodialysis in term of adverse events occuring during dialysis sessions between day 30 and day 120 of treatment and to evaluate: Quality of life evaluated with the KDQOL questionnaire Incidence of cardiovascular events Influence of the technic on cardiovascular, inflammatory and infectious risk factors Mortality

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Disease
Keywords
on line hemodiafiltration, tolerance, quality of life, cardiovascular risk, Hemodialysis patients

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
415 (Actual)

8. Arms, Groups, and Interventions

Arm Title
On line Hemodiafiltration
Arm Type
Active Comparator
Arm Description
Hemodialysis patients treated with on line hemodiafiltration technic
Arm Title
hemodialysis
Arm Type
Other
Arm Description
Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers
Intervention Type
Procedure
Intervention Name(s)
On line Hemodiafiltration
Other Intervention Name(s)
on line HDF, HDF
Intervention Description
3 sessions/week; 3-4 hours per session
Intervention Type
Procedure
Intervention Name(s)
Hemodialysis
Other Intervention Name(s)
conventional hemodialysis
Intervention Description
3 sessions/week; 3-4 hours per session; high flux dialyzers
Primary Outcome Measure Information:
Title
tolerance of "on line" HDF treatment versus conventional high flux hemodialysis in term of adverse events occuring during dialysis sessions
Time Frame
between day 30 and day 120 of treatment
Secondary Outcome Measure Information:
Title
Quality of life evaluated with the KDQOL questionnaire
Time Frame
day 0, 180, 365, 730
Title
Incidence of cardiovascular events
Time Frame
day 180, 365, 730
Title
Influence of the technic on mineral metabolism disturbances
Description
measure of mineral metabolism parameters (Ca, PO4, PTH)
Time Frame
day 180, 365, 730
Title
All cause and cardiovascular mortality
Time Frame
day 180, 365, 730
Title
Influence of the technic on inflammatory parameters
Description
measure of pro-inflammatory cytokines and acute phase reactant proteins
Time Frame
day 180, 365, 730
Title
Influence of the technic on microbiological safety
Description
measure of microbiological purity of dialysate
Time Frame
day 180, 365, 730
Title
Influence of the technic on oxidative stress parameters
Description
measure of oxidative stress markers (AOPP, AGE) and antioxidant systems (vitamin E)
Time Frame
day 180, 365, 730

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient who has signed the written consent form Patient aged > 65 and < 90 years With creatinine clearance < 10 mL/min On dialysis for a minimum of 3 months, with 3 times a week hemodialysis sessions Erythropoietin dosage needed to maintain hemoglobin at a constant level (range of hemoglobin: 9-13 g/dL without any variation of more than 2g/dL for less than 3 months) Without any problem of vascular access Exclusion Criteria: Patient aged < 65 and > 90 years Presence of severe malnutrition (albumin < 20 g/L) Unstable clinical condition Unipuncture or failed vascular access flow Known problems of coagulation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Didier AGUILERA, Dr
Organizational Affiliation
CHG Vichy France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Lynda AZZOUZ, Dr
Organizational Affiliation
CH Roanne France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jean-Marie BATHO, Dr
Organizational Affiliation
CH privé Saint Martin Caen France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Francois COMBARNOUS, Dr
Organizational Affiliation
Clinique du Tonkin Villeurbanne France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Lotfi CHALABI, Dr
Organizational Affiliation
AIDER Montpellier France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Guy DEGREMONT, Dr
Organizational Affiliation
CHG Cambrai France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Maxime HOFFMANN, Dr
Organizational Affiliation
Clinique de la Louvière Lille France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Gérard DESCHODT, Dr
Organizational Affiliation
AIDER Nimes France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Assia DJEMA, Dr
Organizational Affiliation
CHG Cholet France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alain DUBOUST, Dr
Organizational Affiliation
Clinique du Vert Galant, Tremblay en France, France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alexandre DUMOULIN, Dr
Organizational Affiliation
CHLM Beziers France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Baya FADEL-BABBA, Dr
Organizational Affiliation
AGDUC La Tronche France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Enrique FIGUEROA, Dr
Organizational Affiliation
CH Briancon France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Thierry HAAS, Dr
Organizational Affiliation
CMCO Evry France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jean-Michel HARDIN, Dr
Organizational Affiliation
CH Soissons France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Daniel HILLION, Dr
Organizational Affiliation
CHI Poissy France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Guillaume JEAN, Dr
Organizational Affiliation
CRAT Tassin La Demi Lune France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Véronique JOYEUX, Pr
Organizational Affiliation
CHU Pontchaillou Rennes France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Kristian KUNZ, Dr
Organizational Affiliation
AURAL France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Antoine LACAILLE, Dr
Organizational Affiliation
UNHEP Aulnay sous Bois France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jacques LEBLEU, Dr
Organizational Affiliation
Clinique néphrologique Pont Allant Maubeuge France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Vincent LEMAITRE, Dr
Organizational Affiliation
CHG Valenciennes France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mehadji MAAZ, Dr
Organizational Affiliation
CH Louis Pasteur Colmar France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Philippe NICOUD, Dr
Organizational Affiliation
Clinique Centre Vallée Blanche Chamonix France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jean-Paul ORTIZ, Dr
Organizational Affiliation
Polyclinique Saint Roch Cabestany France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jacky POTIER, Dr
Organizational Affiliation
CH Louis Pasteur Cherbourg France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Olivier PUYOO, Dr
Organizational Affiliation
Clinique Néphrologique Occitanie Muret France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Véronique QUERON, Dr
Organizational Affiliation
Polyclinique Francheville Perigueux France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Gilles SCHUTZ, Dr
Organizational Affiliation
Centre HD Provence Aubagne France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Francois MAURICE, Dr
Organizational Affiliation
CHLM Montpellier France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Bruno SEIGNEURIC, Dr
Organizational Affiliation
CHU Larrey Toulouse France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Frederic TOLLIS, Dr
Organizational Affiliation
CHU Angers France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Carlos VELA, Dr
Organizational Affiliation
CH Perpignan France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Francois WAMBERGUE, Dr
Organizational Affiliation
Clinique du Bois Lille France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christian WOLF, Dr
Organizational Affiliation
CH Toulon France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jean-Paul CRISTOL, Pr
Organizational Affiliation
CHU Lapeyronie Montpellier France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Bernard CANAUD, Pr
Organizational Affiliation
CHU Lapeyronie Montpellier France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Universitaire
City
Montpellier
ZIP/Postal Code
34295
Country
France

12. IPD Sharing Statement

Learn more about this trial

Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients

We'll reach out to this number within 24 hrs